MacroGenics director converts 21,165 RSUs to shares
MacroGenics director Scott Koenig reported an RSU conversion into common stock.
Rhea-AI Filing Summary
MacroGenics director Scott Koenig reported an RSU conversion into common stock. On February 15, 2026, he exercised restricted stock units and acquired 21,165 shares of MacroGenics common stock at a stated price of $0 per share, increasing his directly held position to 867,240 shares.
The RSUs were part of a 127,000-unit grant awarded on February 15, 2023. According to the disclosure, 84,670 units had vested before his separation from the company, and 21,165 additional units vested on August 13, 2025 under his Separation Agreement, with each RSU representing one share of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 21,165 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,165 | $0.00 | $0.00 |
Footnotes (2)
- F1. On February 15, 2023, the reporting person was granted 127,000 restricted stock units. Eighty-four thousand, six hundred seventy (84,670) were vested prior to the reporting person's separation from the company and 21,165 units vested upon his separation on August 13, 2025 in accordance with his Separation Agreement.
- F2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MacroGenics (MGNX) director Scott Koenig report?
What is the origin of the 21,165 RSUs reported by MacroGenics (MGNX) director Scott Koenig?
How do Scott Koenig’s RSUs convert into MacroGenics (MGNX) common stock?
Was Scott Koenig’s MacroGenics (MGNX) Form 4 transaction a market purchase or sale?
What does Scott Koenig’s Separation Agreement with MacroGenics (MGNX) provide regarding RSU vesting?
AI-generated analysis. How Rhea-AI works. Not financial advice.